Небиволол восстанавливает сосуды и дыхание после COVID-19, если не поздно: терапевтический потенциал
Терапевтический потенциал и клиническая эффективность небиволола при COVID-19 https://dzen.ru/a/aXJeqsO_an2TSf2Z [1] Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity - PMC [2] β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization - PMC [3] Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 - PMC [4] Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach - PMC [5] s41419-025-08162-2.pdf [6] Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study - PMC [7] Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clinical trial - PMC [8] Network-based transcriptomic analysis identifies the genetic effect of COVID-19 to chronic kidney disease patients: A bioinformatics approach - PMC
Терапевтический потенциал и клиническая эффективность небиволола при COVID-19 https://dzen.ru/a/aXJeqsO_an2TSf2Z [1] Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity - PMC [2] β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization - PMC [3] Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 - PMC [4] Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach - PMC [5] s41419-025-08162-2.pdf [6] Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study - PMC [7] Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clinical trial - PMC [8] Network-based transcriptomic analysis identifies the genetic effect of COVID-19 to chronic kidney disease patients: A bioinformatics approach - PMC